(Q43028510)

12 November 2017

Somatostatin and somatostatin receptors: from basic concepts to clinical applications (English)

1 reference

12 November 2017

Maria Cristina De Martino

series ordinal

1

1 reference

PubMed ID

20541669

12 November 2017

Leo J Hofland

series ordinal

2

1 reference

PubMed ID

20541669

12 November 2017

Steven W J Lamberts

series ordinal

3

1 reference

12 November 2017

1 January 2010

1 reference

Progress in Brain Research

12 November 2017

1 reference

12 November 2017

182

1 reference

12 November 2017

255-280

1 reference

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: pre- and perioperative therapy in patients with neuroendocrine tumors

12 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin analogue phase I trials in neuroendocrine neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Pharmacological approach to acute pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Medical management of thyrotropin-secreting pituitary adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

1 reference

7 January 2021

Somatostatin agonists for treatment of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Perioperative management in distal pancreatectomy: results of a survey in 23 European participating centres of the DISPACT trial and a review of literature

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Systemic complications of acromegaly: epidemiology, pathogenesis, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Medical therapy of pituitary adenomas: effects on tumor shrinkage

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptor subtypes mediate contractility on human colonic smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptor imaging for neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Well-differentiated pancreatic tumor/carcinoma: insulinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

A cortical neuropeptide with neuronal depressant and sleep-modulating properties

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Interrelationships between somatostatin sst2A receptors and somatostatin-containing axons in rat brain: evidence for regulation of cell surface receptors by endogenous somatostatin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Immunoreactive somatostatin is present in discrete cells of the endocrine pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Medical therapy of acromegaly: efficacy and safety of somatostatin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Novel chimeric somatostatin analogs: facts and perspectives.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

In Vitro Characterization of Somatostatin Receptors in the Human Thymus and Effects of Somatostatin and Octreotide on Cultured Thymic Epithelial Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Neuroendocrine tumors. Peptide receptor radionuclide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Identification and characterization of a novel human cortistatin-like peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Experience in treatment of metastatic pulmonary carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptor 2 expression in the human endometrium through the menstrual cycle.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

The role of somatostatin analogues in the treatment of neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Immunohistochemical localization of somatostatin receptor sst2A in human gut and lung tissue: possible implications for physiology and carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Lung carcinoid with Cushing's syndrome: control of serum ACTH and cortisol levels using SMS 201-995 (sandostatin)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin and somatostatin receptors in Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

The pathophysiological consequences of somatostatin receptor internalization and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Intracellular trafficking of somatostatin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Control of catecholamine release and blood pressure with octreotide in a patient with pheochromocytoma: a case report with in vitro studies

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Octreoscan in thyroid-associated ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptor imaging in the diagnosis and treatment of neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

1 reference

7 January 2021

Somatostatin analogs in the diagnosis and treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

New somatostatin analogs: will they fulfil old promises?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Messenger RNA expression of somatostatin receptor subtypes in human and rat gastric mucosae

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Guidelines for acromegaly management: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptor subtype gene expression in pituitary adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Gastroenteropancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptors in the haematopoietic system

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin and its receptor family

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

1 reference

7 January 2021

Dopamine receptor expression and function in corticotroph pituitary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Peptide receptors as molecular targets for cancer diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

In vitro detection of somatostatin receptors in human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Autoradiographic mapping of somatostatin receptors in the rat central nervous system and pituitary.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptors in human prostate and prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Cloning and characterization of a fourth human somatostatin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Pasireotide (SOM230): development, mechanism of action and potential applications

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Selective agonism in somatostatin receptor signaling and regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Pharmacological profile of somatostatin and cortistatin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Function and expression of somatostatin receptors of the endocrine pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

(99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy (GO).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Expression of five somatostatin receptor mRNAs in the human brain and pituitary.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Novel insights in somatostatin receptor physiology.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Novel subtype specific and universal somatostatin analogues: clinical potential and pitfalls

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

The role of somatostatin analogs in Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

The role of cortistatin in the human immune system

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Expression of the somatostatin receptor subtype 4 in intact and inflamed pulmonary tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Highly active cyclic and bicyclic somatostatin analogues of reduced ring size

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Current approaches and perspectives in the therapy of medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin, cortistatin and their receptors in tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

The prophylactic use of octreotide in a patient with ovarian carcinoid and valvular heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Opportunities in somatostatin research: biological, chemical and therapeutic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Somatostatin receptor subtype 2 mediates inhibition of gastrin and histamine secretion from human, dog, and rat antrum

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2982011-4

7 January 2021

10.1016/S0079-6123(10)82011-4

Identifiers

DOI

1 reference

12 November 2017

1 reference

PubMed ID

20541669